Clinical Trial: A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07229911) titled 'A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)' on Nov. 14.

Brief Summary: The main aim of this study is to see if the drug TAK-781 is safe for healthy volunteers and for participants with PSC. The study will also look at how well participants can tolerate TAK-781. In addition, the study will check how the body absorbs, uses, and gets rid of TAK-781 (Pharmacokinetics [PK]), how the drug affects the body (Pharmacodynamics [PD]), and how the body's immune system reacts to TAK-781 (Immunogenicity).

The study consists of two phases (Phase 1a and 1b). Phase 1a include...